Based on the Revolution Medicines Inc stock forecast from 13 analysts, the average analyst target price for Revolution Medicines Inc is USD 59.04 over the next 12 months. Revolution Medicines Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Revolution Medicines Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Revolution Medicines Inc’s stock price was USD 57.37. Revolution Medicines Inc’s stock price has changed by -2.93% over the past week, +16.56% over the past month and +174.89% over the last year.
No recent analyst target price found for Revolution Medicines Inc
No recent average analyst rating found for Revolution Medicines Inc
Company Overview Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Read Less
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) i...Read More
Frequently Asked Questions About Revolution Medicines Inc (RVMD) Stock
Based on ratings from 13 analysts Revolution Medicines Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 24 buy, sell and hold ratings.
Unfortunately we do not have enough data on RVMD's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for RVMD is USD 59.04 over the next 12 months. The maximum analyst target price is USD 82 while the minimum anlayst target price is USD 48.
Unfortunately we do not have enough data on RVMD's stock to indicate if its overvalued.
The last closing price of RVMD's stock was USD 57.37.
The most recent market capitalization for RVMD is USD 9.20B.
Based on targets from 13 analysts, the average taret price for RVMD is projected at USD 59.04 over the next 12 months.
This means that RVMD's stock price may go up by +2.91% over the next 12 months.
We can't find any ETFs which contains Revolution Medicines Inc's stock.
As per our most recent records Revolution Medicines Inc has 443 Employees.
Revolution Medicines Inc's registered address is 700 Saginaw Drive, Redwood City, CA, United States, 94063.
You can get more information about it from Revolution Medicines Inc's website at https://www.revmed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Revolution Medicines Inc (RVMD) Stock
Based on ratings from 13 analysts Revolution Medicines Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 24 buy, sell and hold ratings.
Unfortunately we do not have enough data on RVMD's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for RVMD is USD 59.04 over the next 12 months. The maximum analyst target price is USD 82 while the minimum anlayst target price is USD 48.
Unfortunately we do not have enough data on RVMD's stock to indicate if its overvalued.
The last closing price of RVMD's stock was USD 57.37.
The most recent market capitalization for RVMD is USD 9.20B.
Based on targets from 13 analysts, the average taret price for RVMD is projected at USD 59.04 over the next 12 months.
This means that RVMD's stock price may go up by +2.91% over the next 12 months.
We can't find any ETFs which contains Revolution Medicines Inc's stock.
As per our most recent records Revolution Medicines Inc has 443 Employees.
Revolution Medicines Inc's registered address is 700 Saginaw Drive, Redwood City, CA, United States, 94063.
You can get more information about it from Revolution Medicines Inc's website at https://www.revmed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RVMD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
